Acadian Asset Management
TARO

Acadian Asset Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Acadian Asset Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-630
Closed -$26K – 1839
2023
Q4 		$26K Hold
630
– – ﹤0.01% 1565
2023
Q3 		$23K Sell
630
-248,423
-100% -$9.32M ﹤0.01% 1531
2023
Q2 		$9.41M Sell
249,053
-10,741
-4% -$337K 0.04% 305
2023
Q1 		$6.29M Sell
259,794
-9,807
-4% -$286K 0.03% 401
2022
Q4 		$7.79M Sell
269,601
-1,663
-0.6% -$49.3K 0.04% 328
2022
Q3 		$8.09M Sell
271,264
-34,131
-11% -$1.18M 0.04% 309
2022
Q2 		$11M Sell
305,395
-21,032
-6% -$802K 0.06% 252
2022
Q1 		$14.1M Sell
326,427
-13,934
-4% -$651K 0.06% 259
2021
Q4 		$17M Sell
340,361
-3,662
-1% -$205K 0.06% 234
2021
Q3 		$21.9M Sell
344,023
-3,354
-1% -$232K 0.08% 200
2021
Q2 		$25M Sell
347,377
-3,715
-1% -$273K 0.09% 196
2021
Q1 		$25.9M Sell
351,092
-17,430
-5% -$1.32M 0.1% 188
2020
Q4 		$27.1M Sell
368,522
-5,217
-1% -$335K 0.1% 168
2020
Q3 		$20.5M Sell
373,739
-3,737
-1% -$233K 0.09% 203
2020
Q2 		$25.1M Buy
377,476
+24,436
+7% +$1.64M 0.11% 181
2020
Q1 		$21.6M Buy
353,040
+25,547
+8% +$1.89M 0.12% 155
2019
Q4 		$28.8M Sell
327,493
-2,955
-0.9% -$249K 0.13% 157
2019
Q3 		$24.9M Sell
330,448
-3,345
-1% -$271K 0.11% 182
2019
Q2 		$28.5M Sell
333,793
-26,621
-7% -$2.63M 0.14% 153
2019
Q1 		$39M Buy
360,414
+51,826
+17% +$5.16M 0.17% 133
2018
Q4 		$26.1M Buy
308,588
+27,175
+10% +$2.62M 0.13% 158
2018
Q3 		$27.7M Buy
281,413
+45,483
+19% +$4.92M 0.11% 165
2018
Q2 		$27.3M Buy
235,930
+136,287
+137% +$15M 0.12% 159
2018
Q1 		$9.84M Sell
99,643
-9,614
-9% -$974K 0.04% 308
2017
Q4 		$11.4M Buy
109,257
+66,306
+154% +$7.29M 0.05% 270
2017
Q3 		$4.84M Buy
42,951
+152
+0.4% +$16.5K 0.02% 376
2017
Q2 		$4.8M Buy
42,799
+6,824
+19% +$771K 0.02% 405
2017
Q1 		$4.19M Sell
35,975
-216,723
-86% -$24M 0.02% 451
2016
Q4 		$26.6M Sell
252,698
-305,198
-55% -$32M 0.13% 161
2016
Q3 		$61.7M Sell
557,896
-223,886
-29% -$29.6M 0.31% 94
2016
Q2 		$114M Buy
781,782
+105,215
+16% +$14.9M 0.58% 45
2016
Q1 		$96.9M Buy
676,567
+150,355
+29% +$21.4M 0.49% 59
2015
Q4 		$81.3M Buy
526,212
+67,301
+15% +$9.83M 0.43% 71
2015
Q3 		$65.6M Buy
458,911
+77,803
+20% +$10.9M 0.36% 78
2015
Q2 		$54.8M Buy
381,108
+25,843
+7% +$3.69M 0.27% 105
2015
Q1 		$50.1M Buy
355,265
+20,594
+6% +$3.17M 0.23% 126
2014
Q4 		$49.6M Buy
334,671
+94,860
+40% +$13.9M 0.22% 127
2014
Q3 		$36.9M Buy
239,811
+61,020
+34% +$9.19M 0.18% 148
2014
Q2 		$25.1M Buy
178,791
+139,691
+357% +$15.5M 0.12% 183
2014
Q1 		$4.34M Buy
+39,100
New +$4.26M 0.02% 358

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Acadian Asset Management's TARO Position: Q1 2024 in Review

Acadian Asset Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2024, closing a stake of 630 shares — an estimated $26K sold.

Acadian Asset Management first reported a position in TARO in Q1 2014 and held it in 40 quarters. The position peaked at $114M in Q2 2016. 94 funds tracked by Wall St. Rank hold TARO as of Q1 2024.

  • Acadian Asset Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 630 Taro Pharmaceutical Industries Ltd. shares in Q1 2024, an estimated $26K.
  • Acadian Asset Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2014 and held it in 40 quarters.
  • Acadian Asset Management's Taro Pharmaceutical Industries Ltd. position peaked at $114M in Q2 2016.
  • 94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.